RxDoctor Payments Data

Stanley Myers, MD

Urology · Portland, ORNPI 1740288158

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,364 of the $11,387 with a category attached, or 64.7%. It is spread thinly across 51 manufacturers, the largest accounting for just 20.8%.

$11,387in general payments, 2019–2025

Across 330 payments — averaging $34.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$2K
  • Astellas Pharma US Inc$883
  • Procept Biorobotics Corporation$786
  • EDAP Technomed Inc$664
  • Johnson & Johnson$638
  • Histosonics, Inc.$583
  • plus $5K from 45 others

What the payments were for

  • Travel & lodging$3,36930%
  • Food & beverage$7,36465%
  • Education$6546%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,387 in reported general payments places this provider in the 85th percentile of 153 urology providers in Oregon.

See all urology providers in Oregon

Medicare billing

Part B allowed, 2024
$156,573
Medicare patients
248
Services billed
1,773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron20$21,450
MyrbetriqMirabegron17$15,173
Testosterone Cypionate61$4,555
Tamsulosin Hcl185$3,185
Potassium Citrate ErPotassium Citrate18$2,527
Estradiol11$2,113
Finasteride111$1,295
Pentoxifylline33$1,291
Tadalafil20$1,205
Oxybutynin Chloride80$643
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim103$634
Oxybutynin Chloride ErOxybutynin Chloride23$514
Cephalexin32$449
Ciprofloxacin Hcl41$284
Oxycodone Hcl55$215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$264$21,45020 claims
Astellas Pharma US IncMyrbetriq$883$15,17317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 153 urology providers in Oregon.

Other urology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →